Anticoagulation and stress-induced cardiomyopathy

J Thromb Thrombolysis. 2019 Jan;47(1):1-7. doi: 10.1007/s11239-018-1729-8.

Abstract

Stress-induced cardiomyopathy (SCM), is a reversible cardiomyopathy characterized by transient systolic dysfunction following an acute physiologic stress. Thromboembolism occurs at a high frequency in patients with intracardiac thrombus secondary to SCM, with one systematic review reporting a rate of 33.3%. The risk of thrombus formation following SCM has been associated with left-ventricular (LV) contraction abnormalities, catecholaminergic surge, and other associated comorbidities. However, established guidelines for screening and management of intracardiac thrombus in the setting of SCM do not exist at present due to a lack of sufficient clinical trial data. The purpose of this article is to discuss the pathophysiological theory and previously documented evidence from cases of LV thrombus secondary to SCM, and to present our recommendations for management of intracardiac thrombus secondary to SCM.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • Cardiomyopathies / complications*
  • Cardiomyopathies / drug therapy
  • Cardiomyopathies / etiology
  • Disease Management
  • Humans
  • Stress, Physiological*
  • Thromboembolism / drug therapy
  • Thromboembolism / etiology
  • Thrombosis / drug therapy
  • Thrombosis / etiology*

Substances

  • Anticoagulants